Gilenya Birth Defect Risk Results in Pregnancy Warning in Canada
Canadian health officials warn that use of Gilenya has been linked to an increased risk of congenital malformations in newborms when taken by pregnant women.
Tag Archives: Progressive Multifocal Leukoencephalopathy (PML)
-
-
Stopping Gilenya May Worsen Multiple Sclerosis, FDA Warns
The FDA has issued a new Gilenya warning, indicating that halting treatment of the MS drug can result in worsening symptoms and disability.
-
Commonly Used Drugs Linked To Four Serious Adverse Side Effects: ISMP Report
A number of drugs, including Abilify, Lipitor and Zoloft, were linked to several uncommon, potentially deadly drug side effects in 2017, according to a new report.
-
Tysabri PML Infection Risk Increases With Long-Term Use: Study
A new study into the side effects of Tysabri indicate that the risk of a deadly brain infection increases the longer patients take the drug, and based on whether they've…
-
Rituxan Side Effects May Have Caused Sepsis In Infant: Study
A case study links the side effects of Rituxan use during pregnancy to episodes of sepsis in a newborn whose immune system may have been compromised when the leukemia drug…
-
Tecfidera Lawsuit Filed by Shareholder Over Biogen Ignoring Safety Signals
A shareholder lawsuit against the makers of the MS drug Tecfidera claims the company knew there were safety problems with the drug, but misrepresented its value to investors.
-
Tysabri Brain Infection Side Effects Could Be Mitigated By Early Detection Through MRIs: Study
The findings of a new study suggest that the use of MRIs and other means of early detection could result in better outcomes in Tysabri patients who develop a potentially…
-
Tysabri Lawsuit Claims Manufacturer Delayed PML Brain Test To Maximize Profits
A lawsuit against the makers of Tysabri accuses them of sitting on a test for years that could have helped predict who was in danger of a potentially deadly brain…
-
Gilenya Fails To Slow Primary Progressive Multiple Sclerosis: Study
A new clinical trial reveals that the MS drug Gilenya is ineffective in treating primary progressive multiple sclerosis.
-
Gilenya Brain Infection Problems Lead To FDA Warning Label Update
The FDA warns that Gilenya has been linked to two cases of a deadly brain infection in multiple sclerosis patients who have taken no other immunosuppressant drugs.